- •
Uterine leiomyoma, benign monoclonal tumors, afflict an estimated 60% of reproductive-aged women, with higher rates among African American women.
- •
Leiomyomas are associated with significant medical costs, impaired fertility potential, obstetric complications, and gynecologic morbidity.
- •
Currently, the effective clinical management of leiomyoma is limited by the fact that hysterectomy is the only cure.
- •
New methods of diagnosis, medical and surgical treatments, as well as interventional radiology and
Clinical Management of Leiomyoma
Section snippets
Key points
Pathophysiology
In this section, the pathophysiology of leiomyoma, including molecular mechanisms and genetics, is discussed. In examining the gross appearance of leiomyoma as well as the molecular structure, it has become clear that these benign tumors are composed of altered collagen fibrils, resulting in an altered extracellular matrix (ECM) compared with adjacent myometrium. The distorted ECM is thought to contribute to the increased rigidity of leiomyoma compared with normal myometrium. This understanding
Diagnosis and assessment
In this section, the diagnosis and assessment of leiomyoma, including clinical symptoms and the role of imaging, are discussed.
Most women with uterine fibroids are asymptomatic25, 26; however, women can experience abnormal uterine bleeding (AUB), pelvic pain, bulk symptoms, reproductive dysfunction, sexual dysfunction, and urologic complications. It has been estimated that approximately 20% to 50% of patients with uterine leiomyoma experience symptoms credited to the presence of myomas.27, 28
Fibroids medical therapy
Currently, hysterectomy is the only cure for fibroids, which underscores the need for identification of effective nonsurgical medical treatments, with high efficacy, and a desirable side-effect profile. This section reviews the use of medical treatments, both as adjuvant therapy and as primary therapy. The discussion focuses on gonadotrophin-releasing hormone (GnRH) analogues, selective progesterone receptor (SPRM) modulators, and aromatase inhibitors (AI). The use of levonorgestrel-containing
Uterine artery embolization
Uterine artery embolization (UAE) is a widely accepted, nonsurgical technique used to treat symptomatic uterine fibroids. This technique has been endorsed by the American College of Obstetricians and Gynecologists as safe and effective for women with uterine fibroids who are appropriately selected.76 UAE is ideal for women with symptomatic uterine fibroids who have medical management, are poor surgical candidates, wish to avoid surgery, or wish to retain their uterus.
Women seeking UAE most
Magnetic resonance–guided focused ultrasound surgery
In 2004, the FDA approved the first magnetic resonance--guided focused ultrasound surgery (MRgFUS) device as a noninvasive thermal ablation therapy for uterine fibroids. The technology uses MRI guidance to map and monitor high-intensity ultrasound-focused ablation of fibroid tumors. The goal of therapy is to achieve an increase in temperature within the fibroid leading to coagulation necrosis while avoiding patient discomfort and damage to surrounding structures (eg, bowel, bladder,
Surgical therapies
For women who desire surgery, the most important considerations are size and location (Fig. 1) of the fibroids and fertility potential. Although hysterectomy is the only cure, myomectomy is the only viable surgical option for women who want to maintain an option for future pregnancies. This section reviews surgical options, with a focus on patient selection and outcomes.
Patients who elect conservative surgery should be apprised of their risk of recurrence and likelihood of eventual
Laparoscopic and robotic myomectomy
For appropriate candidates, laparoscopic myomectomy offers the advantage of lower blood loss, more rapid return to normal activities, shorter hospital stays, and a more cosmetically acceptable scar. A large multicenter trial and other clinical investigations have reported uterine rupture after laparoscopic myomectomy, and it has been recommended that women with fibroids greater than 5 cm multiple myomas and deep intramural myomas consider abdominal myomectomy.93 Although there are many
Abdominal myomectomy
Abdominal myomectomy is the preferred surgical option when hysteroscopy or laparoscopy is not an option, or the patient has another indication for laparotomy (Fig. 2). Other recommendations based on earlier studies suggested that women with more than 3 to 4 fibroids or total uterine size greater than 9 cm consider abdominal myomectomy. The increasing experience of surgeons and the advent of robotic technology have made it possible for women with larger uteri to avoid laparotomy. In a recent
Hysterectomy
For women who desire definitive therapy, there are several options, which include vaginal hysterectomy, total laparoscopic hysterectomy (TLH), laparoscopic-assisted vaginal hysterectomy (LAVH), and laparotomy. Like myomectomy, the surgical route is determined by size and location of the fibroids, surgeon experience, and patient preference. In a recent randomized comparison of vaginal hysterectomy in Europe, TLH and LAVH for leiomyoma, the study found vaginal hysterectomy was the faster
Outcomes
Rates of mortality for fibroid surgery are low, and the risk of serious complications is small. Surgical site infection rates vary from 1% to 11%, but most of these are superficial infections. Although rates of deep vein thromboses are high among surgical patients who do not receive prophylaxis, the risk of fatal pulmonary embolism is less than 1%. The risk of postoperative bleeding that requires transfusion is 2% after abdominal hysterectomy, but transfusion rates vary from 2% to 28% with
Summary
Although hysterectomy remains the only cure for fibroids, there are several exciting candidates for medical therapies in the treatment of fibroids. Vitamin D, epigallocatechin gallate (EGCG), or green tea extract, compounds that increase retinoic acid and dietary supplements such as curcumin, all appear to have potential as nonsurgical therapies.
There is evidence to suggest that vitamin D inhibits growth, induces apoptosis in human leiomyoma cell cultures, and may act as an antifibrotic factor.
References (99)
- et al.
Comparison of characteristics of fibroids in African American and white women undergoing premenopausal hysterectomy
Fertil Steril
(2013) - et al.
The estimated annual cost of uterine leiomyomata in the United States
Am J Obstet Gynecol
(2012) - et al.
Myomas and assisted reproductive technologies: when and how to act?
Obstet Gynecol Clin North Am
(2006) - et al.
Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study
Fertil Steril
(2013) - et al.
The health disparities of uterine fibroid tumors for African American women: a public health issue
Am J Obstet Gynecol
(2014) - et al.
Self-reported family history of leiomyoma: not a reliable marker of high risk
Ann Epidemiol
(2013) - et al.
Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma
Matrix Biol
(2012) - et al.
Uterine myomas in adolescents: case reports and a review of the literature
J Pediatr Adolesc Gynecol
(1996) - et al.
Association of seedling myomas with myometrial hyperplasia
Hum Pathol
(2009) - et al.
HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes
Lab Invest
(2000)
Clinical presentation of fibroids
Best Pract Res Clin Obstet Gynaecol
The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata
Obstet Gynecol
Biomarkers in uterine leiomyoma
Fertil Steril
Self-reported heavy bleeding associated with uterine leiomyomata
Obstet Gynecol
Uterine fibroids and gynecologic pain symptoms in a population-based study
Fertil Steril
Clinical features of myomas
Obstet Gynecol Clin North Am
Fibroids and infertility: an updated systematic review of the evidence
Fertil Steril
Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for research and clinical care
Am J Obstet Gynecol
Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas
Obstet Gynecol
Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas
Am J Obstet Gynecol
Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy
Fertil Steril
Diagnostic imaging of myomas
Obstet Gynecol Clin North Am
Ultrasonography and magnetic resonance imaging of uterine fibroids
Obstet Gynecol Clin North Am
Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata?
Fertil Steril
Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata
Fertil Steril
A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata
Fertil Steril
The spectrum of endometrial pathology induced by progesterone receptor modulators
Mod Pathol
Treatment of symptomatic uterine leiomyoma with letrozole
Reprod Biomed Online
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients
Fertil Steril
Intrauterine device use among women with uterine fibroids: a systematic review
Contraception
Persistent vaginal discharge after uterine artery embolization for fibroid tumors: cause of the condition, magnetic resonance imaging appearance, and surgical treatment
Am J Obstet Gynecol
The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids
Fertil Steril
Pregnancy outcomes after treatment for fibromyomata: uterine artery embolization versus laparoscopic myomectomy
Am J Obstet Gynecol
Eligibility and accessibility of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of uterine leiomyomas
Fertil Steril
Hysteroscopic management of large symptomatic submucous uterine myomas
J Minim Invasive Gynecol
Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells
Fertil Steril
Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression
Fertil Steril
Uterine leiomyomas express a molecular pattern that lowers retinoic acid exposure
Fertil Steril
High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence
Am J Obstet Gynecol
The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis
Hum Reprod
Association of age at menarche with increasing number of fibroids in a cohort of women who underwent standardized ultrasound assessment
Am J Epidemiol
Potential risk factors associated with subtypes of uterine leiomyomata
Reprod Sci
Relationship between obesity and uterine leiomyomata
Nutrition
Growth of uterine leiomyomata among premenopausal black and white women
Proc Natl Acad Sci U S A
The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy
Hum Reprod Update
Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia
Cancer Res
Leiomyomata: heritability and cytogenetic studies
Hum Reprod Update
Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene
Gynecol Obstet Invest
Uterine leiomyomas: cytogenetic and histologic profile
Obstet Gynecol
Cited by (40)
Angioleiomyoma in a 52-year-old female wrist: A case report
2023, Radiology Case ReportsBenign Uterine Disease: The Added Role of Imaging
2021, Obstetrics and Gynecology Clinics of North AmericaCitation Excerpt :MRI excels in leiomyoma mapping and gives an accurate International Federation of Gynecology and Obstetrics classification. Indeed, management approaches according to International Federation of Gynecology and Obstetrics classification has been widely proposed.17,19 Types 0 and 1 myomas can be resected by hysteroscopy.42–44
Imaging Spectrum of Benign Uterine Disease and Treatment Options
2020, Radiologic Clinics of North AmericaBenign and malignant pathology of the uterus
2018, Best Practice and Research: Clinical Obstetrics and GynaecologyIdentification of TRADD as a potential biomarker in human uterine leiomyoma through iTRAQ based proteomic profiling
2017, Molecular and Cellular Probes
The authors have nothing to disclose.